The BRAF/+/melanoma patients had higher rates of 2-year recurrence-free survival (RFS) in the entire cohort, as well as in the DT-treated group, compared to those treated with anti-PD1 (Figure 4 and Figure A3 in Appendix B). The gene discussed is BRAF; the disease is melanoma.